IHS Chemical Week

Regions :: North America :: U.S.

ScinoPharm to Invest in U.S. Biologics Firm

11:58 PM MDT | September 1, 2010 | Deepti Ramesh

Active pharmaceutical ingredients (APIs) manufacturer ScinoPharm (Shan-Hua, Taiwan) says it will invest in Tanvex Biologics (Irvine, CA), which specializes in the development of biosimilars and biobetters, as well as the provision of contract research and contract manufacturing services for biologics. ScinoPharm's investment is in the form of tangible assets, intellectual properties, as well as cash, the company says. Financial details of the deal were not disclosed. Tanvex is currently establishing a cGMP facility at San Diego, CA and will have research centers...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa